Latest Rhenman & Partners Asset Management AB Stock Portfolio

Rhenman & Partners Asset Management AB Performance:

2025 Q3: 2.72%YTD: 2.36%2024: 2.56%

Performance for 2025 Q3 is 2.72%, and YTD is 2.36%, and 2024 is 2.56%.

About Rhenman & Partners Asset Management AB and 13F Hedge Fund Stock Holdings

In it's latest 13F Holdings report, Rhenman & Partners Asset Management AB reported an equity portfolio of $903.7 Millions as of 30 Sep, 2025.

The top stock holdings of Rhenman & Partners Asset Management AB are BSX, LLY, ABBV. The fund has invested 4.7% of it's portfolio in BOSTON SCIENTIFIC CORP and 4.5% of portfolio in LILLY ELI & CO.

The fund managers got completely rid off DEXCOM INC (DXCM), HCA HEALTHCARE INC (HCA) and VERONA PHARMA PLC (VRNA) stocks. They significantly reduced their stock positions in TENET HEALTHCARE CORP (THC), MERUS N V (MRUS) and UNIVERSAL HLTH SVCS INC (UHS). Rhenman & Partners Asset Management AB opened new stock positions in MADRIGAL PHARMACEUTICALS INC (MDGL), ADAPTIVE BIOTECHNOLOGIES COR (ADPT) and MINERALYS THERAPEUTICS INC. The fund showed a lot of confidence in some stocks as they added substantially to DOXIMITY INC (DOCS), MOONLAKE IMMUNOTHERAPEUTICS (MLTX) and BIOGEN INC (BIIB).

Rhenman & Partners Asset Management AB Annual Return Estimates Vs S&P 500

Our best estimate is that Rhenman & Partners Asset Management AB made a return of 2.72% in the last quarter. In trailing 12 months, it's portfolio return was -6.92%.

New Buys

Ticker	$ Bought
madrigal pharmaceuticals inc	8,370,540
adaptive biotechnologies cor	7,405,200
mineralys therapeutics inc	6,256,800
stoke therapeutics inc	5,875,000
vera therapeutics inc	3,777,800
rhythm pharmaceuticals inc	3,534,650
united therapeutics corp del	3,353,680
guardant health inc	3,124,000

New stocks bought by Rhenman & Partners Asset Management AB

Additions

Ticker	% Inc.
doximity inc	547
moonlake immunotherapeutics	360
biogen inc	358
edwards lifesciences corp	181
thermo fisher scientific inc	169
viking therapeutics inc	154
apellis pharmaceuticals inc	149
cytokinetics inc	144

Additions to existing portfolio by Rhenman & Partners Asset Management AB

Reductions

Ticker	% Reduced
tenet healthcare corp	-57.17
merus n v	-53.88
universal hlth svcs inc	-53.85
gilead sciences inc	-52.33
elevance health inc	-49.61
natera inc	-46.09
alnylam pharmaceuticals inc	-37.74
royalty pharma plc	-24.85

Rhenman & Partners Asset Management AB reduced stake in above stock

Sold off

Ticker	$ Sold
oscar health inc	-6,691,250
astrana health inc	-4,727,200
inmune bio inc	-411,836
dexcom inc	-13,922,800
verona pharma plc	-10,072,800
summit therapeutics inc	-1,659,840
alcon ag	-5,989,840
hca healthcare inc	-11,408,000

Rhenman & Partners Asset Management AB got rid off the above stocks

Sector Distribution

Rhenman & Partners Asset Management AB has about 94.5% of it's holdings in Healthcare sector.

Sector	%
Healthcare	94.5
Others	5.5

Market Cap. Distribution

Rhenman & Partners Asset Management AB has about 62.1% of it's portfolio invested in the large-cap and mega-cap stocks.

Category	%
LARGE-CAP	50.2
MID-CAP	24.8
MEGA-CAP	11.9
SMALL-CAP	9.7
UNALLOCATED	3.5

Stocks belong to which Index?

About 74.4% of the stocks held by Rhenman & Partners Asset Management AB either belong to S&P 500 or RUSSELL 2000 index.

Index	%
S&P 500	47.9
RUSSELL 2000	26.5
Others	25.6

Top 5 Winners (%)		%
MRUS	merus n v	79.0 %
SNDX	syndax pharmaceuticals inc	64.3 %
RLAY	relay therapeutics inc	50.9 %
XNCR	xencor inc	49.2 %
MIRM	mirum pharmaceuticals inc	44.1 %

Top 5 Winners ($)		$
INSM	insmed inc	7.6 M
ALNY	alnylam pharmaceuticals inc	6.7 M
MRUS	merus n v	4.8 M
IONS	ionis pharmaceuticals inc	4.7 M
ALHC	alignment healthcare inc	4.4 M

Top 5 Losers (%)		%
MLTX	moonlake immunotherapeutics	-54.8 %
ALGN	align technology inc	-29.1 %
INSP	inspire med sys inc	-27.2 %
CNC	centene corp del	-23.4 %
PRCT	procept biorobotics corp	-23.0 %

Top 5 Losers ($)		$
GKOS	glaukos corp	-5.1 M
ISRG	intuitive surgical inc	-4.3 M
ALGN	align technology inc	-4.3 M
PRCT	procept biorobotics corp	-4.2 M
VRTX	vertex pharmaceuticals inc	-3.3 M

Rhenman & Partners Asset Management AB Holdings Map

This heatmap illustrates the top 50 positions within the fund's portfolio.

Current Stock Holdings of Rhenman & Partners Asset Management AB

Rhenman & Partners Asset Management AB has 92 stocks in it's portfolio. About 30.1% of the portfolio is in top 10 stocks. GKOS proved to be the most loss making stock for the portfolio. INSM was the most profitable stock for Rhenman & Partners Asset Management AB last quarter.

Last Reported on: 13 Nov, 2025

Ticker	Namesorted ascending	% Portfolio	Shares Held	$ Value	Type	% Change
ABBV	abbvie inc	3.34	130,375	30,187,000	added	87.93

ABC	cencora inc	2.16	62,375	19,494,100	added	26.33

ABT	abbott labs	1.46	98,500	13,193,100	added	68.38

ACLX	arcellx inc	0.59	65,250	5,357,020	reduced	-2.97

ADPT	adaptive biotechnologies cor	0.82	495,000	7,405,200	new

AKRO	akero therapeutics inc	1.21	230,600	10,948,900	added	16.7

ALGN	align technology inc	1.15	83,000	10,393,300	added	24.81

ALHC	alignment healthcare inc	2.86	1,479,280	25,813,500	added	14.92

ALKS	alkermes plc	0.31	94,000	2,820,000	added	141

ALNY	alnylam pharmaceuticals inc	1.61	31,875	14,535,000	reduced	-37.74

AMEH	astrana health inc	0.00	0.00	0.00	sold off	-100

ANNX	annexon inc	0.28	823,000	2,510,150	added	78.91

APLS	apellis pharmaceuticals inc	0.58	232,250	5,255,820	added	149

ATEC	alphatec hldgs inc	0.03	18,000	261,720	new

AXSM	axsome therapeutics inc	2.32	172,800	20,986,600	added	90.31

BIIB	biogen inc	0.85	55,000	7,704,400	added	358

BMRN	biomarin pharmaceutical inc	1.12	186,650	10,109,000	added	24.72

BRKR	bruker corp	0.56	154,315	5,013,690	added	25.14

BSX	boston scientific corp	4.73	438,000	42,761,900	added	47.97

CAH	cardinal health inc	1.63	94,000	14,754,200	added	70.91